Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech Corporation

industry_trends_dossier

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

signals

swot_dossier

news_advanced

news_impact_assignment_basic

news_impact_assignment_advanced

news_processing_basic

news_processing_advanced

peers

valuation

customer_profile

news_basic

NASDAQ:LEGN

Legend Biotech

Last Close

45.93

03/05 20:00

Market Cap

8.26B

Beta: −0.08

Volume Today

679.86K

Avg: 810.09K

PE Ratio

−39.80

PFCF: −29.36